What is CM-Path?

More than half a million pounds has been committed to a new initiative called Cellular Molecular Pathology (CM-Path) which aims to boost UK pathology research.

A collaboration of NCRI Partners has committed £635,000 to the initiative over five years to boost the UK’s research activity in cellular molecular pathology – the science of understanding disease at the level of tissue and cells, including their DNA.

The CM-Path programme, which launched in early 2016, brings together experts from pathology and other fields to build a stronger base of people and resources for the UK to undertake pathology research. The new funding will also help to boost activity in the centres of excellence where pathologists investigate cancer biology and treatment.

The development of the initiative was carried out by a dedicated working group of pathology experts in the Experimental Cancer Medicine Centres (ECMC) network. It will be funded as a collaborative venture between 10 of the NCRI partner organisations: Bloodwise, Breast Cancer Now, Cancer Research UK, the Chief Scientist Office (Scotland), the Department of Health (England), Health and Care Research Wales (Welsh Government), Health and Social Care (N Ireland), the Medical Research Council, Prostate Cancer UK and Tenovus Cancer Care.

CM-Path Funders

funders